Arcellx (ACLX) Other Accumulated Expenses (2021 - 2025)
Arcellx's quarterly Other Accumulated Expenses came in at $4.4 million in Q4 2025, down 48.89% year-on-year from $8.5 million in Q4 2024, and down 35.6% quarter-over-quarter from $6.8 million in Q3 2025.
Arcellx has reported Other Accumulated Expenses for 5 years, with the latest figure at $4.4 million in Q4 2025.
- For the quarter ending Q4 2025, Other Accumulated Expenses fell 48.89% year-over-year to $4.4 million; the trailing twelve-month figure through Dec 2025 stood at $4.4 million (down 48.89% YoY), and the FY2025 full-year result was $4.4 million, down 48.89% from the prior year.
- Other Accumulated Expenses for Q4 2025 stood at $4.4 million, down from $6.8 million in the prior quarter.
- The five-year high for Other Accumulated Expenses was $26.9 million in Q2 2024, with the low at $164000.0 in Q1 2022.
- Average Other Accumulated Expenses over 5 years is $8.9 million, with a median of $7.4 million recorded in 2025.
- Year-over-year, Other Accumulated Expenses soared 4720.12% in 2023 and plunged 72.91% in 2025.
- Tracing ACLX's Other Accumulated Expenses over 5 years: stood at $1.8 million in 2021, then jumped by 71.66% to $3.1 million in 2022, then surged by 162.34% to $8.2 million in 2023, then rose by 3.86% to $8.5 million in 2024, then plunged by 48.89% to $4.4 million in 2025.
- The last three Other Accumulated Expenses figures came in at $4.4 million (Q4 2025), $6.8 million (Q3 2025), and $8.5 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Arcellx | 6.48 Bn | 6.48 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 4.36 Mn |
| Sep 30, 2025 | 6.77 Mn |
| Jun 30, 2025 | 8.51 Mn |
| Mar 31, 2025 | 7.36 Mn |
| Dec 31, 2024 | 8.53 Mn |
| Sep 30, 2024 | 24.99 Mn |
| Jun 30, 2024 | 26.90 Mn |
| Mar 31, 2024 | 23.63 Mn |
| Dec 31, 2023 | 8.21 Mn |
| Sep 30, 2023 | 10.22 Mn |
| Jun 30, 2023 | 5.02 Mn |
| Mar 31, 2023 | 7.91 Mn |
| Dec 31, 2022 | 3.13 Mn |
| Sep 30, 2022 | 1.84 Mn |
| Jun 30, 2022 | 1.66 Mn |
| Mar 31, 2022 | 164,000.00 |
| Dec 31, 2021 | 1.82 Mn |